|
Forecast
Period
|
2026-2030
|
|
Market
Size (2024)
|
USD
12.70 Billion
|
|
CAGR
(2025-2030)
|
6.11%
|
|
Fastest
Growing Segment
|
Injectable
drug delivery
|
|
Largest
Market
|
West
India
|
|
Market
Size (2030)
|
USD
18.05 Billion
|
Market Overview
The India Drug Delivery Devices Market was valued at USD 12.70 billion in 2024 and is expected to reach USD 18.05 billion by 2030 with a CAGR of 6.11% during the forecast period.
The Drug Delivery Devices Market encompasses the global industry
dedicated to the development and sales of medical devices specifically designed
to deliver medications and therapeutic agents into the body in a controlled
manner. These devices play a crucial role in the treatment of a wide range of
illnesses and diseases, offering diverse options from simple syringe systems to cutting-edge nanotechnology. With various segments based on
the route of administration, including oral, injectable, topical, ocular,
nasal, and pulmonary, this market caters to the specific needs of patients
across different medical domains.
Technological advancements continue to drive
innovation in drug delivery devices, enabling more precise and targeted
treatment options for patients. The rising prevalence of chronic diseases and the growing geriatric population are significant factors driving this market's growth.
As demand for effective, convenient drug delivery solutions continues to rise, the Drug Delivery Devices Market remains a dynamic, evolving sector
within the healthcare industry.
Download Free Sample Report
Key Market Drivers
Rising
Prevalence of Chronic Diseases
India is witnessing a significant rise in the prevalence of chronic diseases, with non-communicable diseases (NCDs) accounting for 60% of all deaths in 2019, up from 37% in 1990. This surge has created an urgent need for efficient drug-delivery devices. The number of diabetic patients is expected to reach nearly 93 million by 2030, and chronic obstructive pulmonary disease (COPD) was the second leading cause of death in 2019. Given that 21% of India's elderly population—projected to reach 158.7 million by 2025 has at least one chronic condition, the demand for devices that ensure precise medication administration has risen substantially.
Drug delivery devices, such as insulin pens and inhalers, play a crucial role in empowering patients to self-administer medication. The market for insulin pens is dynamic, with Indian drugmakers like Eris Lifesciences and Lupin preparing to capitalize on an opportunity estimated at Rs 600-800 crore following Novo Nordisk's decision to phase out some of its pen products. The increasing popularity of home healthcare services from providers like Kailash Healthcare and Care24 has further fueled demand for these devices, as they provide patients with medical equipment assistance and convenience in their own homes. Recognizing this need, the government is working to enhance accessibility and affordability through initiatives like the National Health Mission (NHM), which provides essential drugs free of cost in public health facilities.
The escalating prevalence of chronic diseases in India is directly influencing the surge in demand for drug delivery devices, and this trend is expected to persist. Continuous efforts to improve access and affordability, supported by both private and public sectors, will further drive the adoption of these devices, ensuring better disease management for affected individuals.
Technological
Advancements in Medical Device Manufacturing
Technological advancements in medical device manufacturing are revolutionizing the landscape of drug delivery devices in India. With the introduction of smart, connected, and miniaturized drug-delivery devices, including novel technologies such as nanoparticles, liposomes, and microneedles, demand has surged, particularly for chronic disease management. These advanced devices, including innovations such as drug-eluting stents and insulin pens, ensure precise, controlled drug delivery, enhancing treatment outcomes.
The COVID-19 pandemic has accelerated the adoption of telemedicine and remote healthcare, further fueling the demand for these devices. Through remote monitoring, which has seen significant growth in rural and underserved regions, patients and healthcare providers can effectively track medication adherence and measure treatment effectiveness, making healthcare more efficient and accessible. In addition, India's growing middle class, rising healthcare expenditure, and government initiatives to boost domestic medical device manufacturing are driving demand.
The government has launched several programs, including the "Scheme for Strengthening the Medical Device Industry" and a Production Linked Incentive (PLI) Scheme that provides a 5% incentive on incremental sales to eligible companies, to bolster domestic production and reduce import dependency. This surge in demand not only addresses India's current healthcare challenges but also sets the stage for a future in which every individual has access to effective, personalized healthcare. By leveraging technological innovation in the medical device sector, India is not only transforming its healthcare system but also creating opportunities for improved healthcare delivery and better health outcomes for all.
Rapid
Growth of The Biopharmaceutical Industry
The biopharmaceutical industry in India is experiencing unprecedented growth, driven by several factors. One key driver is India's positioning as a hub for affordable biopharmaceutical production, which has seen the country's bioeconomy grow from $10 billion in 2014 to $165.7 billion in 2024. This has led to the establishment of state-of-the-art manufacturing facilities and research centers in hubs like Hyderabad and Bengaluru, fostering innovation and driving the development of novel drug therapies.
Another contributing factor to the industry's growth is the rise in chronic diseases in India, coupled with an aging population. The chronic therapy market segment, which saw a 9.9% growth in early 2025, is a major driver of the pharmaceutical industry. As the prevalence of diseases such as diabetes and cardiovascular disorders continues to increase, there is an urgent need for effective drug delivery systems. Patient-centric devices, including inhalers, injectors, and controlled-release implants, play a crucial role in ensuring the efficient and precise administration of medication. These devices not only improve therapeutic impact but also enhance patient compliance, ultimately leading to better health outcomes.
The ongoing innovation in biopharmaceuticals necessitates parallel advancements in drug delivery technology. With the development of complex biological drugs, such as monoclonal antibodies (mAbs) and gene therapies, there is a growing demand for sophisticated delivery systems. In 2024, India approved several new mAbs for import and marketing, including enfortumab vedotin for urothelial cancer and nivolumab for lung cancer. This requires integrating advanced materials and smart delivery mechanisms into drug-delivery devices, with injectable delivery emerging as the fastest-growing segment.
Therefore, the rapid growth of the biopharmaceutical industry in India, which now accounts for 49% of the country's total biotechnology output, is undeniably linked to the escalating demand for drug-delivery devices. As the industry continues to expand, there will be a continuous need for innovative and reliable drug-delivery solutions that meet the evolving needs of patients and healthcare professionals.
Rising
Investments by The Drug Manufacturers In The Clinical Trials
India's booming pharmaceutical industry has been making substantial investments in clinical trials, further amplifying demand for cutting-edge drug-delivery devices. The nation became the third-largest destination for clinical trials globally in 2024, registering approximately 18,000 new trials—a significant increase from the previous year. The introduction of innovative drug delivery systems, including inhalers, transdermal patches, and insulin pens, serves as a testament to the industry's commitment to revolutionize healthcare.
These novel devices hold immense potential to enhance the efficacy of drug administration, making treatments more user-friendly and significantly improving patient compliance. Smart insulin pens, for instance, have demonstrated the ability to increase a patient's time-in-range. The ongoing investments in clinical trials by drug manufacturers not only underscore their unwavering dedication to improving healthcare outcomes but also play a pivotal role in ensuring the safety and efficacy of new drug-delivery devices before they are introduced to the market.
Bristol Myers Squibb has invested over US$100 million for early-stage drug development and plans to more than double its 23 active clinical trials in India by 2026. This unwavering commitment to research and development showcases the industry's determination to prioritize patient well-being. The influx of investment underscores the urgent need to update and enhance drug-delivery mechanisms, supported by regulations like the New Drugs and Clinical Trials Rules, 2019, which are being amended to halve approval timelines. These transformative developments are poised to pave the way for groundbreaking, effective, and patient-centric solutions, thereby fueling nationwide demand for advanced drug-delivery devices.
The significant strides made in drug delivery technologies are a testament to the pharmaceutical industry's unwavering dedication to providing superior healthcare management. As investments continue to flow into clinical trials, the market for drug delivery devices in India is poised for exponential growth in the coming years. This rapid evolution in drug-delivery mechanisms holds the key to a brighter, healthier future for all.
Key Market Challenges
High
Risk of Needlestick Injuries
Despite the increased need for effective drug delivery devices in India, there is a growing concern over the high risk of needlestick injuries, which is negatively impacting the demand. Needlestick injuries pose a significant risk to
healthcare personnel, potentially leading to the transmission of blood-borne
pathogens, including HIV, Hepatitis B, and Hepatitis C. This risk factor is
especially relevant in a densely populated country like India, where the
healthcare system is often under pressure and safety protocols may not always
be strictly adhered to.
The fear of needlestick injuries is leading to a hesitancy in the adoption of
drug delivery devices, with many individuals preferring oral medication or
non-invasive treatment options instead. This shift in preference is disrupting market growth for drug delivery devices in India. To address
this ongoing issue, it is crucial to develop safer, more secure delivery systems that can regain consumer confidence and meet demand effectively. By
implementing advanced safety features and ensuring strict adherence to safety
protocols, the development of such delivery systems can mitigate the risks
associated with needlestick injuries. This, in turn, will help to restore
consumer trust and drive the demand for drug delivery devices in India.
Lack
of Awareness About Drug Delivery Devices
The
demand for Drug Delivery Devices (DDD) in India is currently experiencing a
significant downturn. This trend can be attributed to a general lack of
awareness about these devices, especially among people residing in rural and
semi-urban areas. Many individuals remain largely uninformed about the
existence, usage, and numerous benefits of DDDs.
These innovative devices are
specifically designed to deliver drugs into the human body in a controlled, precise manner, thereby enhancing the treatment of various medical conditions.
However, due to the absence of adequate knowledge and understanding, potential
users continue to rely on traditional methods of drug intake, which in turn
reduces the demand for sophisticated drug delivery systems. The problem is further compounded by inadequate marketing strategies and
insufficient training of healthcare professionals.
This lack of promotion and
education contributes to the prevailing unawareness surrounding DDDs. To
reverse this concerning trend, it is crucial to initiate extensive awareness
campaigns about DDDs, targeting both consumers and healthcare providers. These
campaigns should emphasize the immense benefits of using these devices for
effective drug administration, ensuring that individuals are well-informed and
empowered to make informed decisions about their healthcare. By increasing
awareness and understanding, we can pave the way for a greater adoption of DDDs
and improve the overall quality of healthcare delivery in India.
Key Market Trends
Increasing Funding from the Government & Private Organizations
In India, demand for drug delivery devices has surged in recent years. This surge can be attributed to a substantial increase in funding from both government and private organizations. These organizations have recognized the vital role that drug delivery devices play in enhancing the efficiency of drug administration and improving patient outcomes.
Government initiatives, such as the National Health Mission (NHM) and Ayushman Bharat, have been instrumental in driving this growth. These initiatives have not only increased their investment in healthcare, with the 2024-25 Union Budget allocating INR 89,287 crore to public health, but also prioritized the development and acquisition of innovative drug-delivery devices through schemes like the Promotion of Research and Innovation in Pharma MedTech Sector (PRIP), with an outlay of ₹5,000 crore, and the Production Linked Incentive (PLI) scheme for medical devices. As a result, healthcare providers across the country have witnessed an influx of funding that has not only bolstered the availability of these devices but also facilitated extensive research and development.
Private organizations, including large pharmaceutical companies and health-focused NGOs, have also played a significant role in this landscape, with private equity deals in the pharmaceutical sector totaling $77.3m in the fourth quarter of 2023 alone. These organizations have recognized the importance of investing in advanced drug delivery systems and have allocated substantial resources to support their development and acquisition. This collaborative effort between the public and private sectors has led to the introduction of more advanced and effective delivery systems, meeting the evolving needs of healthcare providers and patients alike.
The overall effect of this funding surge is a rapid increase in demand for drug delivery devices in India. As healthcare providers strive to offer the best possible care to their patients, they are increasingly relying on these devices to ensure accurate and efficient drug administration, supported by the Ayushman Bharat program which has established over 2 lakh Ayushman Arogya Mandirs and created over 73 crore health accounts as of January 2025. This growing demand not only reflects healthcare providers' commitment to delivering optimal care but also highlights the transformative impact that advanced drug-delivery devices can have on patient outcomes.
Innovative
Strategies Adopted by The Key Market Players
Innovative
strategies adopted by key market players in India are significantly driving the
demand for drug delivery devices. These companies are not only focusing on
research and development but also investing in cutting-edge
technologies to introduce new and improved devices. These devices aim to
provide effective, safe, and patient-friendly methods of drug delivery. For
instance, the implementation of drug-eluting stents has been transformative in
improving patient outcomes in cardiovascular conditions. These stents deliver medication to the affected area, reducing the risk of complications and enhancing treatment effectiveness. Similarly, the rise in insulin pens
has revolutionized the management of diabetic conditions. These pens offer a
convenient and precise way to administer insulin, improving patient compliance
and overall diabetes management.
Collaborations and partnerships have become a prevailing trend in the industry.
This has led to greater technological exchange and expanded product portfolios. Companies are joining forces to leverage their strengths and
resources, leading to the development of more advanced and diverse drug-delivery devices. To ensure accessibility to advanced healthcare, companies are
strategically targeting rural areas. They are focusing on providing affordable, user-friendly devices that healthcare professionals can easily use in these areas. This effort aims to bridge the healthcare gap between urban and
rural regions, making essential treatments more accessible to all.
The introduction of digitized devices and telemedicine services has created a
paradigm shift in the industry. These innovations offer remote patient
monitoring and adherence tracking, providing real-time data to healthcare
providers. This not only improves patient care but also helps identify potential issues or complications early. These advancements in drug-delivery devices have not only heightened patient trust but also
demonstrated treatment efficacy. The expanded market reach has driven growth in drug delivery devices in India, making significant contributions to
the healthcare industry and improving the overall quality of patient care.
Segmental Insights
Route of Administration Insights
Based on the Route of Administration, the Injectable drug delivery emerged as the fastest-growing segment in the Indian market for Drug Delivery Devices during the forecast period. Chronic diseases such as diabetes, cancer, autoimmune disorders, and cardiovascular conditions are increasingly prevalent in India. These conditions often necessitate long-term management with medications that are unsuitable for oral administration due to factors such as low bioavailability or gastrointestinal degradation. A growing number of biologic therapies, including monoclonal antibodies, insulin, and vaccines, require injectable delivery to ensure their effectiveness. These therapies have significantly advanced the treatment of chronic diseases and are increasingly being adopted in India.
The introduction of user-friendly self-injection devices, such as pen injectors and auto-injectors, has made injectable treatments more accessible, enabling patients to administer their own medications at home and improving compliance and convenience. For instance, insulin pens have become increasingly popular among patients with diabetes. Additionally, innovations such as needle-free injectors that use high pressure to deliver medication through the skin are helping mitigate discomfort and fear associated with injections, driving greater acceptance.
Injectable drugs offer more targeted delivery, directly administering the medication to the bloodstream or specific areas in the body, which is especially beneficial for localized treatments such as cancer or rheumatoid arthritis. Furthermore, controlled-release formulations allow for the gradual release of drugs, reducing the need for frequent dosing and enhancing patient compliance. There is a growing trend toward personalized medicine and the use of biologic therapies, which often require injectable delivery. Injectable medications often require fewer doses or are available in sustained-release formulations, which can improve patient compliance and lead to better health outcomes for chronic conditions. As India’s pharmaceutical market continues to expand, many companies are focusing on injectable formulations to meet both domestic and international demand. India’s emerging role as a manufacturing hub for biologics and injectables has further expanded the market for these products.
Application Insights
Based on application, diabetes emerged as the dominating segment in the Indian market for Drug Delivery Devices in 2024. This is due to the
sustained rise in population, coupled with improvements in healthcare
infrastructure and accessibility, which has led to a larger pool of individuals
seeking medical attention and preventive measures. This demographic shift
underscores the importance of addressing chronic conditions like diabetes,
which require ongoing management and treatment. The increasing disposable
income among consumers has enabled greater spending on healthcare and wellness
products. As people prioritize their health and well-being, they are more
inclined to invest in technologies and solutions that help manage chronic diseases such as diabetes effectively. This trend is particularly
evident in emerging economies where rising affluence is translating into
greater healthcare expenditure. The sustained growth trajectory of the diabetes
segment underscores the pressing need to address diabetes as a public health
priority. Governments, healthcare providers, and industry stakeholders are
recognizing the importance of investing in preventive measures, early
diagnosis, and effective management strategies to mitigate the burden of
diabetes on individuals and healthcare systems alike.
Download Free Sample Report
Regional Insights
Based on region, West India emerged as the dominating region in the India Drug Delivery
Devices Market in 2024. This dominance can be attributed to the high concentration of
reputable pharmaceutical companies, supported by a robust healthcare
infrastructure and substantial investments in cutting-edge research and
development activities within these states.
The region's strategic
geographical location, favorable government policies, and well-established
supply chain networks contribute significantly to its prominence in the market.
In Maharashtra, for example, the city of Mumbai serves as a key hub for
pharmaceutical manufacturing and research, housing numerous renowned
pharmaceutical companies and research institutions. The state's well-developed
healthcare infrastructure, with top-notch hospitals and medical facilities, creates a conducive environment for the development and adoption of advanced drug-delivery devices.
Gujarat,
on the other hand, boasts a strong pharmaceutical presence with a wide range of
pharmaceutical companies operating in the state. The government's proactive
approach to promoting research and development, along with attractive incentives for pharmaceutical companies, has further bolstered the state's position as a major player in the drug-delivery devices market. The Western
region's strategic geographical location plays a crucial role in its prominence
within the market.
Situated on the western coast of India, it provides
convenient access to both domestic and international markets, facilitating
efficient distribution and export of drug delivery devices. The
region benefits from well-established supply chain networks, ensuring the smooth, timely delivery of products to healthcare providers and end users.
Recent Development
- In January 2025, the Indian Central Drugs Standard Control Organization (CDSCO) issued a draft of the Medical Devices (Amendment) Rules, 2024, proposing a new risk-based classification system for medical devices, including drug delivery systems.
- In
August 2024, a multi-institutional team led by researchers from IIT Bhilai, in
collaboration with scientists from Shiv Nadar Institution and Shri Rawatpura
Sarkar Institute of Pharmacy, Chhattisgarh, successfully developed an
innovative insulin delivery platform. This hydrogel-based drug delivery system
is designed to release insulin in a controlled manner in response to elevated
blood glucose levels, mimicking the natural insulin secretion process of
healthy pancreatic cells. The study, led by Dr. Suchetan Pal, Assistant
Professor in the Department of Chemistry at IIT Bhilai, offers a promising,
safe, and efficient solution for insulin-dependent diabetic patients.
- In
April 2024, Dr. Reddy’s Laboratories Ltd. announced the launch of Nerivio, a
non-invasive wearable device for migraine management, in Germany through its
step-down subsidiary Betapharm. This marks the company’s entry into the
European digital therapeutics market. Nerivio is approved by the U.S. Food and
Drug Administration (USFDA) and is CE-mark certified in Europe. The device was
launched in India by Dr. Reddy’s in 2023 and is supported by the company’s
unique patient support program, ‘M-Free,’ in the country. Additionally, Dr.
Reddy’s entered into an exclusive agreement with Theranica, a digital
therapeutics company specializing in advanced neuromodulation devices for
migraine and other pain conditions, to market and distribute Nerivio across
multiple markets.
- In
March 2024, the Union Minister for Chemicals & Fertilizers and Health &
Family Welfare virtually launched 27 greenfield bulk drug park projects and 13
greenfield medical device manufacturing plants under the PLI Scheme. The PLI
scheme aims to facilitate the production of 41 bulk drugs with a total
investment of USD 820.10 Million over the scheme’s duration from 2020-21 to
2029-30. Additionally, 26 applicants for medical device manufacturing have been
approved for 138 products under the scheme, with a total financial allocation
of USD 404.14 Million for the period 2020-21 to 2027-28.
Key Market Players
- Pfizer Ltd.
- Novartis India Ltd.
- GlaxoSmithKline Pharmaceuticals Ltd.
- India Medtronic Private Ltd.
- Cardinal Health International India Pvt Ltd.
- B. Braun Medical (India) Pvt. Ltd.
- Sun Pharmaceutical Industries Ltd.
- 3M India Ltd.
- Cipla Ltd.
- Bayer Zydus Pharma
|
By
Devices
|
By
Route of Administration
|
By
Application
|
By
End User
|
By Region
|
|
Syringe
Inhaler
Nebulizer
Transdermal Patch
|
Oral Drug Delivery
Injectable Drug
Delivery
Topical Drug
Delivery
Others
|
Cancer
Respiratory Diseases
Diabetes
Cardiovascular Diseases
Others
|
Hospitals
Diagnostic Centres
Ambulatory Surgery Centres
Others
|
West
North
South
East
|
Report
Scope:
In
this report, the India Drug Delivery Devices Market has been segmented into the
following categories, in addition to the industry trends which have also been
detailed below:
- India Drug Delivery Devices Market, By Devices:
o
Syringe
o
Inhaler
o
Nebulizer
o
Transdermal Patch
- India Drug Delivery Devices Market, By Route of Administration:
o
Oral Drug Delivery
o
Injectable Drug Delivery
o
Topical Drug Delivery
o
Others
- India Drug Delivery Devices Market, By Application:
o
Cancer
o
Respiratory Diseases
o
Diabetes
o
Cardiovascular Diseases
o
Others
- India Drug Delivery Devices Market, By End User:
o
Hospitals
o
Diagnostic Centres
o
Ambulatory Surgery Centres
o
Others
- India Drug Delivery Devices Market, By Region:
o
North
o
South
o
West
o
East
Competitive
Landscape
Company
Profiles: Detailed
analysis of the major companies present in the India Drug Delivery Devices
Market.
Available
Customizations:
India
Drug Delivery Devices Market report with the given market data, TechSci
Research offers customizations according to a company's specific needs. The
following customization options are available for the report:
Company
Information
- Detailed analysis and profiling of
additional market players (up to five).
India
Drug Delivery Devices Market is an upcoming report to be released soon. If you
wish an early delivery of this report or want to confirm the date of release,
please contact us at [email protected]